ZIMMER BIOMET HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $18.31B
- P/E (TTM)
- 23.1
- Dividend yield
- 1.01%
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $2.18B | $1.03 | $2.07 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 28, 2026 | Before market open | $2.09B | $1.22 | $2.09 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 10, 2026 | Before market open | $2.24B | $0.70 | $2.42 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $2.00B | $1.16 | $1.90 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $2.08B | $0.77 | $2.07 |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | Before market open | $1.91B | $0.91 | $1.81 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 6, 2025 | Before market open | $2.02B | $1.20 | $2.31 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | Before market open | $1.82B | $1.23 | $1.74 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | Before market open | $1.94B | $1.18 | $2.01 |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted Diluted EPSnon-GAAP | full-year 2026 | $8.47 to $8.59 | Raised |
| Foreign Currency Exchange Impact | full-year 2026 | 0.5% | Maintained |
| Reported Revenue ChangeGAAP | full-year 2026 | 3.9% to 4.9% growth | Raised |
| Constant Currency Revenue Changenon-GAAP | full-year 2026 | 3.4% to 4.4% growth | Raised |
| Organic Constant Currency Revenue Changenon-GAAP | full-year 2026 | 2.25% to 3.25% growth | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Zimmer Biomet filed with the SEC
Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
The following items of the 2025 Form 10-K are being recast as reflected in this Exhibit 99.1:
Other events · EX-99.1 to Form 8-K
Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Zimmer Biomet Increases Share Repurchase Expectations —
Regulation FD disclosure · EX-99.1 to Form 8-K
Zimmer Biomet Announces Chief Financial Officer Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full-Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Zimmer Biomet Completes Acquisition of Monogram Technologies
Other events · EX-99.1 to Form 8-K
Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
MOVING YOU FORWARD July 14, 2025 ZBH
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zimmer Biomet Announces Definitive Agreement to Acquire Monogram
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Zimmer Biomet Appoints Kevin Thornal as
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Zimmer Biomet Completes Acquisition of Paragon 28
Other events · EX-99.1 to Form 8-K
Zimmer Biomet Announces Upcoming Changes to
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Fourth Quarter and Full-Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28
Regulation FD disclosure · EX-99.1 to Form 8-K
ZBH Acquisition of Paragon 28 2024 Investor Day January 28, 2025
Regulation FD disclosure · EX-99.2 to Form 8-K
Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
The following items of the 2023 Form 10-K are being recast as reflected in this Exhibit 99.1:
Other events · EX-99.1 to Form 8-K
Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Zimmer Biomet Announces Appointment of
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full-Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Zimmer Biomet Announces Appointment of
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Zimmer Biomet Announces Leadership Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
Fourth Quarter and Full-Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Zimmer Biomet Announces Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Zimmer Biomet Announces Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Zimmer Biomet Announces Appointment of
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Zimmer Biomet Announces First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
The Company is also updating how it presents geographic and product category sales to allow for better comparability with its peers.
Results of operations · EX-99.1 to Form 8-K
Zimmer Biomet Announces Completion of ZimVie Spinoff
Material agreement · Acquisition or disposition completed · New financial obligation · Other events · EX-99.1 to Form 8-K
We previously announced plans to separate our spine and dental businesses from our core orthopedic businesses. The separation
Regulation FD disclosure · EX-99.1 to Form 8-K
Investor Day February 7, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K